Your browser doesn't support javascript.
Infection with SARS-CoV-2 among children with asthma: evidence from Global Asthma Network.
Chiang, Chen-Yuan; Ellwood, Philippa; Ellwood, Eamon; García-Marcos, Luis; Masekela, Refiloe; Asher, Innes; Badellino, Héctor; Sanz, Alberto Bercedo; Douros, Konstantinos; El Sony, Asma; Diaz, Carlos González; Rodríguez, Ms Albi; Moreno-Salvador, Ana; Pérez-Martini, Luis F; Filho, Nelson Rosário; Shpakou, Andrei; Sulaimanov, Shairbek; Tavakol, Marzieh; Valverde-Molina, José; Yousef, Abdullah A; Pearce, Neil.
  • Chiang CY; International Union Against Tuberculosis and Lung Disease, Paris, France.
  • Ellwood P; Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • Ellwood E; Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • García-Marcos L; Department of Paediatrics, Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Masekela R; Department of Paediatrics, Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Asher I; Pediatric Allergy and Pulmonology Units, Virgen de la Arrixaca University Children's Hospital, University of Murcia and IMIB Bioresearch Institute, Murcia, Spain.
  • Badellino H; ARADyAL Allergy Network, Edificio Departamental-Laib, El Palmar, Murcia, Spain.
  • Sanz AB; Department of Paediatrics and Child Health, Nelson R Mandela School of Clinical Medicine, College of Health Sciences, University of KwaZulu Natal, Durban, South Africa.
  • Douros K; Department of Paediatrics, Child and Youth Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • El Sony A; Pediatric Respiratory Medicine Department, UCES University and Clínica Regional del Este, Corrientes, San Francisco, Argentina.
  • Diaz CG; Cantabrian Health Service, Valdecilla Research Institute (IDIVAL), Dobra Health Center, Torrelavega, Cantabria, Spain.
  • Rodríguez MA; School of Medicine, 3rd Department of Pediatrics, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Moreno-Salvador A; Epidemiological Laboratory (Epi-Lab) for Public Health, Research and Development, Khartoum, Sudan.
  • Pérez-Martini LF; Department of Pediatrics, University of the Basque Country, Bilbao, Vizcaya, Spain.
  • Filho NR; UPV/EHU, Basurto University Hospital, Bilbao, Vizcaya, Spain.
  • Shpakou A; Pediatric Pneumology and Allergy Unit, Hospital Universitario Doce de Octubre, Madrid, Spain.
  • Sulaimanov S; Pediatric Allergy Unit, Virgen de la Arrixaca University Children's Hospital, University of Murcia, Spain.
  • Tavakol M; Asociación Guatemalteca de Neumología y Cirugía de Tórax, Guatemala, Ciudad, Guatemala.
  • Valverde-Molina J; Hospital de Clinicas, Federal University of Parana, Curitiba, Parana, Brasil.
  • Yousef AA; Department of Theory of Physical Culture and Sport Medicine, Yanka Kupala State University of Grodno, Grodno, Belarus.
  • Pearce N; Kyrgyz-Russian Slavic University, Bishkek City, Kyrgyzstan.
Pediatr Allergy Immunol ; 33(1): e13709, 2022 01.
Article in English | MEDLINE | ID: covidwho-1546397
ABSTRACT

BACKGROUND:

Clinical presentations of coronavirus disease 2019 (COVID-19) among children with asthma have rarely been investigated. This study aimed to assess clinical manifestations and outcome of COVID-19 among children with asthma, and whether the use of asthma medications was associated with outcomes of interest.

METHODS:

The Global Asthma Network (GAN) conducted a global survey among GAN centers. Data collection was between November 2020 and April 2021.

RESULTS:

Fourteen GAN centers from 10 countries provided data on 169 children with asthma infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was asymptomatic in 58 (34.3%), mild in 93 (55.0%), moderate in 14 (8.3%), and severe/critical in 4 (2.4%). Thirty-eight (22.5%) patients had exacerbation of asthma and 21 (12.4%) were hospitalized for a median of 7 days (interquartile range 3-16). Those who had moderate or more severe COVID-19 were significantly more likely to have exacerbation of asthma as compared to those who were asymptomatic or had mild COVID-19 (adjusted odds ratio (adjOR) 3.97, 95% CI 1.23-12.84). Those who used inhaled bronchodilators were significantly more likely to have a change of asthma medications (adjOR 2.39, 95% CI 1.02-5.63) compared to those who did not. Children who used inhaled corticosteroids (ICS) did not differ from those who did not use ICS with regard to being symptomatic, severity of COVID-19, asthma exacerbation, and hospitalization.

CONCLUSIONS:

Over dependence on inhaled bronchodilator may be inappropriate. Use of ICS may be safe and should be continued in children with asthma during the pandemic of COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Asthma / COVID-19 Type of study: Observational study / Prognostic study Limits: Child / Humans Language: English Journal: Pediatr Allergy Immunol Journal subject: Allergy and Immunology / Pediatrics Year: 2022 Document Type: Article Affiliation country: Pai.13709

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Asthma / COVID-19 Type of study: Observational study / Prognostic study Limits: Child / Humans Language: English Journal: Pediatr Allergy Immunol Journal subject: Allergy and Immunology / Pediatrics Year: 2022 Document Type: Article Affiliation country: Pai.13709